Open an account

Keros Therapeutics

KROS · NASDAQ

$11.40+$0.34 (+3.07%)TodayMarket closed ·
Prev close $11.06

About KROS

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 78 full-time employees. The company went IPO on 2020-04-08. The firm is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, elritercept (KER-065), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. KER-065 is designed to act as a ligand trap and inhibit the biological effects of myostatin and activin A. Its lead product candidate, rinvatercept, is being developed for the treatment of neuromuscular diseases. Elritercept is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Employees
87
Headquarters
Lexington, Massachusetts
Listed
Apr 8, 2020
Sector
Health Care
Industry
Biotechnology
Website
kerostx.com

KROS key statistics

Market cap
226.03M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
177.38K
Volume
153.39K
Open price
$11.04
High today
$11.67
Low today
$11.04
52 Week high
$22.55
52 Week low
$9.69

Keros Therapeutics (KROS) at a glance

Keros Therapeutics (KROS) last traded at $11.40, with a market cap of 226.03M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.04 and $11.67. The current price is 3.3% above the day's low and 2.3% below its high.

Volume so far is 153.39K shares, in line with the average of 177.38K shares a day.

Over the past year Keros Therapeutics has ranged from $9.69 to $22.55, and now sits 13% of the way up that range.

Keros Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.45 per share against an estimate of -$1.37.

The average analyst price target is $20.20, 77.2% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

60%of 5 analyst ratings say Buy
  • Buy60.0%
  • Hold40.0%
  • Sell0.0%
Price target · 7 analystsAvg $20.20
Low
$16.16
Now
$11.40
High
$26.25

KROS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 559.2% on average.

  1. Q3 FY24: reported -$1.41 per share against an estimate of -$1.30
  2. Q4 FY24: reported -$1.14 per share against an estimate of -$1.00
  3. Q1 FY25: reported $3.62 per share against an estimate of -$0.2479
  4. Q2 FY25: reported -$0.76 per share against an estimate of -$1.15
  5. Q3 FY25: reported -$0.18 per share against an estimate of -$1.07
  6. Q4 FY25: reported -$0.86 per share against an estimate of -$0.6413
  7. Q1 FY26: reported -$1.21 per share against an estimate of -$1.04
  8. Q2 FY26: reported -$1.45 per share against an estimate of -$1.37

KROS news

  • Press releasePRNewswire

    A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

  • Press releasePRNewswire

    ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

  • Nabaparna Bhattacharya

    Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst

  • Press releasePRNewswire

    ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

  • Press releasePRNewswire

    ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

  • Press releasePRNewswire

    ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

  • Press releasePRNewswire

    ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

  • Anthony Noto

    Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price

Similar companies

Companies in the same industry as Keros Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.